Justification of the Change From 10% to 30% for the Immunohistochemical HER2 Scoring Criterion in Breast Cancer
Yan‐Hui Liu(Hainan University), Jie Xu(Dalian Medical University), Li Li(Army Medical University), Donglan Luo(Guangdong General Hospital), Fangping Xu(Guangdong Academy of Medical Sciences), Xin-lan Luo(Guangdong General Hospital), Heng-guo Zhuang(Guangdong General Hospital), Fen Zhang(Kunming University of Science and Technology), Jianyu Rao(University of California, Los Angeles)
Cited by 21
Related Papers
Cancer incidence and mortality in China, 2016
|Journal of the National Cancer Center|2022|1.6k
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA
|Cell Research|2011|1.2k
Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells
|Autophagy|2012|180
Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells
|Clinical Cancer Research|2017|136
PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer
|International Journal of Oncology|2015|131